PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 34,000 shares, a drop of 47.5% from the January 31st total of 64,800 shares. Based on an average trading volume of 3,330,000 shares, the short-interest ratio is currently 0.0 days. Currently, 4.0% of the shares of the company are sold short.

PainReform Trading Up 1.6 %

PRFX opened at $3.15 on Friday. The business’s 50 day moving average is $3.28 and its 200-day moving average is $2.83. The stock has a market cap of $456,750.00, a PE ratio of -0.02 and a beta of 0.64. PainReform has a twelve month low of $1.73 and a twelve month high of $61.20.

Institutional Investors Weigh In On PainReform

An institutional investor recently bought a new position in PainReform stock. Apollon Wealth Management LLC acquired a new stake in shares of PainReform Ltd. (NASDAQ:PRFX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned 9.23% of PainReform at the end of the most recent reporting period. 37.28% of the stock is currently owned by institutional investors and hedge funds.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.